09:50 AM EST - XPhyto Therapeutics Corp. : Announced an update on its oral disintegrating film drug delivery programs. XPhyto's wholly owned German subsidiary, Vektor Pharma TF GmbH, is currently advancing two sublingual ODF development programs for the delivery of the active pharmaceutical ingredients cannabidiol and tetrahydrocannabinol. The US Food & Drug Administration (FDA) and European Medicines Agency (EMA) have approved CBD based medicines for the treatment of severe childhood forms of Epilepsy, specifically Dravet syndrome and Lennox-Gastaut syndrome. THC based medicines have been approved for the treatment of nausea associated with cancer chemotherapy and for the treatment of anorexia associated with weight loss in AIDS patients. The registered formulation for CBD is a lipophilic solution in sesame oil and for THC it is a soft gelatin capsule filled with THC in a sesame oil carrier. XPhyto Therapeutics Corp.
shares C.XPHY are trading up 3 cents at $2.69.
